Clinical trials: Dengue
Dengue Hemorrhagic Fever
Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients
Design and Outcomes This research study is designed as open-label, sequential dose-escalating clinical trial. There will be two phases of enrollment.
- Trial name
- PKIDEN (NCT03432442)
- Testing
- Ivermectin
- Where
- Thailand
- Volunteers
- 24 people
- Sponsor
- Mahidol University
Mass Screening
Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol
The purpose of the study is to screen blood donors for the presence of NS1 antigen of the dengue virus at the American Red Cross in Puerto Rico region (and Monroe County, Florida) using the Platelia Dengue NS1 Ag enzyme…
- Trial name
- NCT01226173
- Testing
- Bio-Rad Platelia Dengue NS1 Ag test
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 182,353 people, healthy volunteers welcome
- Sponsor
- Bio-Rad Laboratories
Dengue
An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Brazil
The purpose of this study is to estimate the incidence of dengue infection in children and adults in geographically distinct locations of Brazil.
- Trial name
- NCT01751139
- Testing
- Blood sample collection, Data collection
- Where
- 5 sites in Brazil
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue Fever
Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore
Dengue fever is an acute febrile illness transmitted by mosquitoes, which affects half the world's population. There are 96 million symptomatic infections, 500,0000 hospitalisations and 25,000 deaths per year attributed to the…
- Trial name
- NCT02569827
- Testing
- Celgosivir, Modipafant 50mg, Modipafant 100mg
- Where
- Singapore
- Sponsor
- Singapore General Hospital
Dengue
Study of AT-752 in Healthy Subjects
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-752 in healthy subjects
- Trial name
- NCT04722627
- Testing
- AT-752
- Where
- Australia
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
DENGUE
Implementation Research of New Dengue Vector Control Tools
This project will provide new insights concerning how to reduce dengue transmission by means of cost-effective and sustainable implementation strategies of vector control methods.
- Trial name
- NCT00883441
- Testing
- Insecticide treated curtains and insecticide treated covers
- Where
- 2 sites in Thailand, Venezuela
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria, Dengue
Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR
Rural communities involved in agriculture are often at highest risk of insect-borne diseases in Southeast (SE) Asia. Skin-applied insect repellents may prove a useful means of reducing mosquito-borne diseases for those people…
- Conditions
- Malaria, Dengue, Japanese Encephalitis
- Trial name
- NCT00938379
- Testing
- 20% deet insect repellent
- Where
- Laos
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Dengue Fever
Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients
Its a double-blind placebo controlled multicenter study involving confirmed dengue patients who are hospitalized.168 Patients will be enrolled according to specific inclusion \& exclusion criteria and they will be divided into…
- Trial name
- NCT06945679
- Testing
- CPLE
- Where
- Bangladesh
- Volunteers
- 184 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Vaccine Hesitancy
Dengue Vaccine Hesitancy Among International Travelers
The goal of this cross-sectional study is to study dengue vaccine hesitancy among 390 international travelers who visit the Hospital for Tropical Diseases, Bangkok, and three public sites which are the area near the Grand Palace…
- Trial name
- NCT06418854
- Testing
- Questionnaire
- Where
- Thailand
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00094705
- Testing
- rDEN2/4delta30(ME) Vaccine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever, Papaya Leaf Extract
To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia
The goal of this clinical trial is to evaluate whether Carica papaya leaf extract (CPLE) can improve platelet counts in children aged 2 to 12 years diagnosed with dengue fever and thrombocytopenia.
- Conditions
- Dengue Fever, Papaya Leaf Extract, Pediatric Patients
- Trial name
- papaya leaf (NCT07172100)
- Testing
- Carica Papaya Leaf Extract Group, standard treatment
- Where
- Pakistan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ziauddin Hospital
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00831012
- Testing
- rDEN3delta30/31-7164
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Hemorrhagic Fever
Gut Leakage' in Dengue
Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the…
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Intestinal Disease, Ascites
- Trial name
- GLiD (NCT07602920)
- Where
- Bangladesh
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Dengue Hemorrhagic Fever
Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus
Dengue fever, which is caused by dengue viruses, is a major health problem in subtropical regions of the world. There are four different forms (serotypes) of dengue virus that can cause dengue fever.
- Trial name
- NCT00458120
- Testing
- rDEN1delta30, rDEN2/4delta30(ME)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus
Genetic Determinants of the Antiviral Immune Response in Oceanian Populations
Oceania's populations, including Melanesians, are paying a heavy price for dengue fever, which has been circulating actively in the region since the Second World War.
- Trial name
- GEDIPOP (NCT06432855)
- Testing
- Blood collection, saliva collection
- Where
- New Caledonia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
The aim of the study was to assess and describe the booster effect of a CYD dengue vaccine dose administered 4 to 5 years after the completion of a 3-dose vaccination schedule.
- Trial name
- NCT02623725
- Testing
- CYD Dengue Vaccine (5-dose formulation)
- Where
- 5 sites in Brazil, Colombia and 3 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Hemorrhagic Fever
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
The purpose of this study is to generate immunogenicity and safety data in preparation for efficacy studies in Latin America. Primary Objectives: To describe the immune response to dengue viruses before and after each vaccination…
- Trial name
- NCT01187433
- Testing
- Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus, NaCl 0.9%, Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children
The purpose of this study is to evaluate the safety and effectiveness of two different formulations of an investigational dengue vaccine (T-DEN) against a placebo vaccine when two doses are given six months apart to adults and…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Shock Syndrome
- Trial name
- NCT00468858
- Testing
- T-DEN-Post-Transfection F17, T-DEN-Post-Transfection F19
- Where
- 11 sites in Puerto Rico
- Volunteers
- 636 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue
Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso
The Integrated Management of Childhood Illness (IMCI) guideline has been implemented in Burkina Faso and is used across primary health facilities to assess children under the age of 5 years.
- Trial name
- NCT04582474
- Testing
- Dengue module and rapid diagnostic tests
- Where
- 2 sites in Burkina Faso
- Volunteers
- 335 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Dengue Fever, Dengue Haemorrhagic Fever
Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine
Primary objectives: To assess how dengue vaccine efficacy varies across participant subgroups regarding polymorphism in human leukocyte antigen (HLA) alleles of interest.
- Trial name
- NCT02827162
- Where
- Thailand
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company